Thornburg Investment Management’s Corcept Therapeutics CORT Stock Holding History

Thornburg Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-64,962	Closed	-$472K	–	270
2016 Q4	$472K	Sell	64,962 -134,800	-67%	-$1.06M	﹤0.01%	271
2016 Q3	$1.3M	Hold	199,762	–	–	0.01%	244
2016 Q2	$1.09M	Sell	199,762 -200,016	-50%	-$1.04M	0.01%	247
2016 Q1	$1.87M	Hold	399,778	–	–	0.01%	235
2015 Q4	$1.99M	Buy	399,778 +65,600	+20%	+$296K	0.01%	251
2015 Q3	$1.26M	Buy	+334,178	New	+$1.7M	0.01%	256

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thornburg Investment Management's CORT Position: Q1 2017 in Review

Thornburg Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 64,962 shares — an estimated $472K sold.

Thornburg Investment Management first reported a position in CORT in Q3 2015 and held it in 6 quarters. The position peaked at $1.99M in Q4 2015. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

Thornburg Investment Management reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
Thornburg Investment Management sold 64,962 Corcept Therapeutics shares in Q1 2017, an estimated $472K.
Thornburg Investment Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 6 quarters.
Thornburg Investment Management's Corcept Therapeutics position peaked at $1.99M in Q4 2015.
135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Thornburg Investment Management's 13F filing for Q1 2017, filed 9 May 2017.